Novo Nordisk (NOVO) Q4 2024 earnings summary

Executive summary

• Achieved 26% sales and operating profit growth in 2024, serving over 45 million patients, with strong performance in diabetes and obesity care and significant R&D progress in obesity pipeline.

• Completed acquisition of three Catalent sites, expanding global manufacturing capacity from 11 to 14 sites.

• Obesity care sales surged 57% to DKK 65.1 billion, with Wegovy and Saxenda expanding globally.

• Rare disease sales increased 9%, with strong growth in rare endocrine disorders and new product launches.

• Major R&D milestones achieved, including positive results for CagriSema, semaglutide 7.2 mg, and amycretin trials.

Financial highlights

• Full-year sales reached DKK 290.4 billion, up 26% at constant exchange rates; operating profit rose to DKK 128.3 billion with a 44.2% margin.

• Net profit increased 21% to DKK 101.0 billion; diluted EPS up 22% to DKK 22.63.

• Gross margin stable at 84.7%; EBITDA up 32% to DKK 147.4 billion.

• Free cash flow was negative DKK 14.7 billion, mainly due to the Catalent acquisition.

• DKK 64.3 billion returned to shareholders via dividends and buybacks; 2024 dividend up 21% to DKK 11.40.

Outlook and guidance

• 2025 sales growth expected at 16–24% at constant exchange rates, with operating profit growth at 19–27%.

• Free cash flow for 2025 forecast at DKK 75–85 billion; CAPEX around DKK 65 billion.

• Effective tax rate for 2025 anticipated at 21–23%.

• No share buyback planned for 2025 due to increased CAPEX.

• Guidance includes continued supply constraints and pricing pressure.